Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

DISEASE CHARACTERISTICS:

• Must have received a BEAM (cytarabine, etoposide, melphalan, carmustine)-conditioned autologous stem cell transplantation for any of the following high-risk lymphomas:
• Diffuse large B-cell lymphoma as defined by:
• Induction failure but with response to salvage therapy
• Relapse less than one year after completion of induction therapy
• Elevated lactate dehydrogenase (LDH) at relapse
• Stage III/IV disease at relapse
• Positive PET scan after induction or salvage therapy
• Age ≤ 75 and ≥ 60 years
• Follicular lymphoma as defined by:
• Progressive disease after two or more prior regimens
• Transformed to aggressive lymphoma but still chemotherapy sensitive
• Not felt to be a good candidate for an allogeneic transplantation
• Hodgkin lymphoma as defined by:
• Primary refractory disease
• Relapse less than one year after completion of induction therapy
• Relapse with PET-positive disease after salvage therapy
• Relapsed refractory and not felt to be a good candidate for an allogeneic transplantation
• Mantle cell lymphoma
• Chemotherapy-sensitive disease after induction therapy
• Chemotherapy-sensitive relapsed disease and not felt to be a good candidate for an allogeneic transplantation
• T-cell non-Hodgkin lymphoma (NHL)
• Peripheral T-cell lymphoma not otherwise specified and one or more of the following at diagnosis:
• High LDH
• Marrow involvement
• Age > 60 years
• Low platelet count
• Relapsed chemotherapy-sensitive disease
• Angioimmunoblastic lymphadenopathy with dysproteinemia
• Anaplastic lymphoma kinase-negative anaplastic NHL
• Enteropathy-associated T-cell NHL
• Natural killer (NK)/T-cell NHL and stage III/IV disease at diagnosis
• NK blastic NHL

PATIENT CHARACTERISTICS:

• ECOG (Eastern Cooperative Oncology Group) /WHO performance status 0-2
• ANC (absolute neutrophil count) ≥ 1,000/μL
• Platelet count ≥ 75,000/μL
• Total bilirubin ≤ 1.5 mg/dL
• AST (aspartate aminotransferase)/ALT (Alanine transaminase) ≤ 2 x upper limit of normal (ULN)
• Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 50 mL/min
• No severe or uncontrolled systemic illness
• Patients must be able to swallow capsules
• Negative pregnancy test
• Not pregnant or nursing
• Fertile patients must use at least two adequate barrier methods of contraception during study and for 90 days after completion of study therapy
• No other malignancy within the past 5 years other than nonmelanoma skin cancer, carcinoma in situ of the cervix, or a malignancy considered by their physician to be at less than 30% risk of relapse
• No congenital long QT syndrome
• No significant history of uncontrolled cardiac disease (i.e., uncontrolled hypertension, unstable angina, myocardial infarction within the past 6 months, or uncontrolled congestive heart failure)
• No active bacterial, fungal, or viral infection
• No known HIV infection
• No active hepatitis B and/or hepatitis C infection
• No other medical condition, including mental illness or substance abuse, deemed by the Investigator(s) to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results

PRIOR CONCURRENT THERAPY:

• Recovered from the majority of the toxicities from the autologous transplantation (must have returned to their pretransplant baseline or have no greater than grade I extramedullary toxicity Common Toxicity Criteria for Adverse Effects[CTCAE 3.0])
• No prior treatment with a histone deacetylase (HDAC) inhibitor (e.g., depsipeptide, MS-275, LAQ-824, belinostat, valproic acid)
• More than 4 weeks since prior and no concurrent class Ia, Ib, or Ic antiarrhythmic drugs
• No other concurrent antineoplastic chemotherapy or biologic therapy
• No concurrent radiotherapy, unless for local control of bone pain
• Irradiated area for pain management should be as small as possible and lesions within the irradiated field cannot be used for response
• No concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of vorinostat (SAHA)